Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) EBIT: 2017-2024

Historic EBIT for Kiniksa Pharmaceuticals International (KNSA) over the last 8 years, with Dec 2024 value amounting to -$45.6 million.

  • Kiniksa Pharmaceuticals International's EBIT rose 348.72% to $24.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.2 million, marking a year-over-year increase of 245.43%. This contributed to the annual value of -$45.6 million for FY2024, which is 81.04% down from last year.
  • According to the latest figures from FY2024, Kiniksa Pharmaceuticals International's EBIT is -$45.6 million, which was down 81.04% from -$25.2 million recorded in FY2023.
  • Kiniksa Pharmaceuticals International's 5-year EBIT high stood at $9.8 million for FY2022, and its period low was -$157.4 million during FY2020.
  • Moreover, its 3-year median value for EBIT was -$25.2 million (2023), whereas its average is -$20.3 million.
  • In the last 5 years, Kiniksa Pharmaceuticals International's EBIT skyrocketed by 106.24% in 2022 and then crashed by 357.81% in 2023.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's EBIT (Yearly) stood at -$157.4 million in 2020, then climbed by 0.46% to -$156.6 million in 2021, then skyrocketed by 106.24% to $9.8 million in 2022, then plummeted by 357.81% to -$25.2 million in 2023, then tumbled by 81.04% to -$45.6 million in 2024.